Home > Analytics > SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS
Intrinsic Value | Fundamental Analysis

BOM : 543064     NSE : SUVENPHAR    
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap]
Debt : Low
Updated:
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward
Pledged Shares : None or < 25%
Feb 07,2023
Price(EOD): ₹ 488.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
Pharmaceuticals & Drugs
MCap: ₹ 12,439.76 Cr
Value of ₹ 1 Lac invested in SUVEN PHARMACEUTICALS
on Mar 09,2020 (price: ₹ 168.00)

₹ 1 L

₹ 2.91 L

1W : -0.7% 1M : -0.8% 1Y : -11.8%
COMMUNITY POLL
for SUVEN PHARMACEUTICALS
Please provide your vote to see the results
SUVEN PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
Industry Peers & Returns1W1M1Y
SUVEN PHARMACEUTICALS -0.7% -0.8% -11.8%
SUN PHARMACEUTICAL INDUSTRIES -0.8% -0.3% 15.9%
DIVIS LABORATORIES -18.1% -20% -34.8%
CIPLA -0.1% -4.2% 8.1%
DR REDDYS LABORATORIES 2.1% 4.1% -0.5%
TORRENT PHARMACEUTICALS 0.1% -0.9% 13.9%
ABBOTT INDIA 1.3% -6.2% 29.7%
ZYDUS LIFESCIENCES 10.1% 11.4% 15.4%
ALKEM LABORATORIES 1.1% 1.3% -13.2%

FUNDAMENTAL ANALYSIS OF SUVEN PHARMACEUTICALS

 
Fundamentals Score
[ Q(TTM): Dec2022, Y: Mar2022
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]

Insights 💡 SUVENPHAR is one of the top 35% companies with good fundamentals ! Discover More →

VALUATION OF SUVEN PHARMACEUTICALS

 
Valuation Score
[As on : Feb 07,2023 ]

Ratio Consolidated
P/E
P/B
P/S
32.82
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 378.99 Cr
[Latest Qtr - Dec2022 - Consolidated Results ]

8.14
P/B Calculated based on Book Value of Rs 1,527.18 Cr
[Latest Year - Mar2022 - Consolidated Results ]

9.32
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,334.82 Cr
[Latest Qtr - Dec2022 - Consolidated Results ]

Financial Ratios →

Insights 💡 SUVENPHAR is one of the potential top 29% undervalued companies ! Discover More →

FAIR VALUE OF SUVEN PHARMACEUTICALS

 
Model Discount(-)/
Premium(+)
EV/EBIDTA
EV/Sales
Price/Sales
-17%
-31%
-31%

Insights 💡 You can learn about various Valuation techniques to calculate Intrinsic Value
with our bestselling video course Value Investing - The Ultimate Guide
Take Me There →

SHARE PRICE MOMENTUM OF SUVEN PHARMACEUTICALS



SUVEN PHARMACEUTICALS vs SENSEX


Insights 💡 You can learn about Basics of Stock Marketing Investing
with our bestselling video course Stock Marketing Investing Simplified
Take Me There →

DEBT OF SUVEN PHARMACEUTICALS

Year Debt/Equity ratio
Standalone Consolidated
2022
2021
2020
Avg_3yrs
0.06
0.13
0.24
0.14
0.06
0.12
0.22
0.13
[Last Annual Data : Mar2022]
Financial Ratios →

PLEDGED PROMOTER SHARES OF SUVEN PHARMACEUTICALS

Pledged Promoter Shares
0 %
As on : Dec2022

If less than 25%

Good
If between 25% and 50% Neutral
If greater than 50% Bad
Shareholding Pattern →

QTRLY RESULTS OF SUVEN PHARMACEUTICALS

Consolidated Q-o-Q Y-o-Y
Revenue
Op Profit
Profit Before Tax
Profit After Tax
27.07%
46.87%
48.35%
49.5%
-9.66%
-21.14%
-38.99%
-32.7%
QtrlyTrend
0
Latest Qtr: Dec2022
Quarterly Result Analysis →


SUVEN PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE 500 -0.3% -3.2% -2.4%
S&P BSE 400 MIDSMALLCAP -0.3% -2.7% -3.1%
S&P BSE ALLCAP -0.4% -3.3% -2.6%
S&P BSE MIDSMALLCAP -0.5% -3.2% -4.6%
S&P BSE 250 SMALLCAP -0.8% -3% -6.9%
NSE Indices1W1M1Y
NIFTY 500 -0.2% -3.2% -2.6%
NIFTY MID SMALL400 -0.4% -3% -3.2%
NIFTY500 MULTICAP 50:25:25 -0.4% -3.2% -3.5%
NIFTY SMALLCAP250 -1.2% -3.5% -9%

You may also like the below Video Courses


FAQ about SUVEN PHARMACEUTICALS


Is SUVEN PHARMACEUTICALS good for long term investment?

As on Feb 07,2023, the Fundamentals of SUVEN PHARMACEUTICALS look Strong and hence it may be good for long term investment! See Financial Performance of SUVEN PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!

Is SUVEN PHARMACEUTICALS UnderValued or OverValued?

As on Feb 07,2023, SUVEN PHARMACEUTICALS is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!

What is the Intrinsic Value of SUVEN PHARMACEUTICALS ?

As on Feb 07,2023, the Intrinsic Value of SUVEN PHARMACEUTICALS is Rs. 705.40 estimated based on Median of the 3 historical models.
Fair Value [Median EV / EBIDTA Model] : Rs. 585.26
Fair Value [Median EV / Sales Model] : Rs. 705.40
Fair Value [Median Price / Sales Model] : Rs. 705.71
Estimated Median Fair Value of SUVEN PHARMACEUTICALS : Rs. 705.40

The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.

Is SUVEN PHARMACEUTICALS trading at a Premium or Discount?

As on Feb 07,2023, SUVEN PHARMACEUTICALS is trading at a Discount of -31% based on the estimates of Median Intrinsic Value!

SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].